Background: Chronic Kidney Disease (CKD) is an emerging disease that causes morbidity, mortality and affects patient's quality of life (QoL). Objectives: To assess and compare dimensions of QoL in the different stages of CKD patients and also to identify the factors affecting QoL. Data and methods: A cross-sectional study was carried out for a period of 8 months in the Dept. of Nephrology. The inclusion criterion of the study is patients above 18 years age diagnosed with CKD stage 3-5 and patients undergoing maintenance haemodialysis. The patients were assessed for QoL using European-QoL-5-dimensional (EQ-QoL-5D) and visual analog scale (VAS) questionnaires. Results: Out of 210 patients, most of the patients were in the age group 51-65 years (43.33%) and the mean age of study population was 52 ± 16.04. In the present study, most of the patients were males (79.04%). The most common comorbidities were hypertension (90%) and 51% of diabetes mellitus (DM). The mean EQ-5D index scores of the CKD stage 3, 4, 5 and 5D patients were 0.77 ± 0.09, 0.67 ± 0.10, 0.62 ± 0.12 and 0.50 ± 0.15 and the mean VAS scores for these stages were 74.10 ± 7.68, 66.52 ± 10.90, 66.45 ± 8.80 and 55.04 ± 12.82 respectively. Conclusion: The most commonly affected domains were usual activities (79%), pain (76.20%) and anxiety/depression (71.91%). Factors such as age (> 65 yrs), BMI (Underweight and Obese), educational background (Illiterate), Unemployment, domiciliary status (Rural), number of medications (> 11) had significant association with EQ-5D index and VAS scores (p-0.000). It was found that QoL was impaired in stage 5D compared to other stages (p-0.000).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.